In terms many issues of the selectivity and mechanisms of action remained unresolved, selective NET inhibitor has now been developed to treat a variety of brain-related disorders, including depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD) and cocaine dependence [1-4]. The gene discussed is SLC6A2; the disease is post-traumatic stress disorder.